These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 1283787)

  • 1. Non-radioactive assay of AFP, hCG, and uE3 from dried blood specimens: a low-cost alternative for maternal screening for trisomy 21.
    Verloes A; Schoos R; Koulischer L
    Prenat Diagn; 1992 Dec; 12(12):1073-4. PubMed ID: 1283787
    [No Abstract]   [Full Text] [Related]  

  • 2. Preliminary evidence for associations between second-trimester human chorionic gonadotropin and unconjugated oestriol levels with pregnancy outcome in Down syndrome pregnancies.
    Benn PA
    Prenat Diagn; 1998 Apr; 18(4):319-24. PubMed ID: 9602476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advent of maternal serum markers for Down syndrome screening.
    Loncar J; Barnabei VM; Larsen JW
    Obstet Gynecol Surv; 1995 Apr; 50(4):316-20. PubMed ID: 7540276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second-trimester maternal serum analyte levels associated with fetal trisomy 13.
    Saller DN; Canick JA; Blitzer MG; Palomaki GE; Schwartz S; Blakemore KJ; Haddow JE
    Prenat Diagn; 1999 Sep; 19(9):813-6. PubMed ID: 10521837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prediction of adverse pregnancy outcome using low unconjugated estriol in the second trimester of pregnancy without risk of Down's syndrome.
    Kim SY; Kim SK; Lee JS; Kim IK; Lee K
    Yonsei Med J; 2000 Apr; 41(2):226-9. PubMed ID: 10817024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Screening for Down syndrome using triple marker testing in the second trimester of pregnancy].
    Lesin J; Skrablin S; Durić K; Suchanek E; Muzinić D; Kalafatić D; Kuvacić I; Zlopasa G; Plavec A
    Lijec Vjesn; 2003; 125(3-4):55-60. PubMed ID: 12899094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of gravidity and parity on the parameters used in serum screening for trisomy 21.
    Zimmermann R; Streicher A; Huch R; Huch A
    Prenat Diagn; 1995 Aug; 15(8):781-2. PubMed ID: 7479601
    [No Abstract]   [Full Text] [Related]  

  • 8. [AFP, uE3, beta-hCG levels applied for prenatal diagnosis of Down's syndrome].
    Liao S; Wang Y; Ye G
    Zhonghua Fu Chan Ke Za Zhi; 1997 Nov; 32(11):655-8. PubMed ID: 9639764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for Down syndrome during the first and second trimesters: impact of risk estimation parameters.
    Forest JC; Massé J; Rousseau F; Moutquin JM; Brideau NA; Bélanger M
    Clin Biochem; 1995 Aug; 28(4):443-9. PubMed ID: 8521600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prenatal screening using maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol: two-year experience in a health maintenance organization.
    McDuffie RS; Haverkamp AD; Stark CF; Haverkamp C; Barth CK
    J Matern Fetal Med; 1996; 5(2):70-3. PubMed ID: 8796771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maternal serum screening for fetal Down syndrome in women less than 35 years of age using alpha-fetoprotein, hCG, and unconjugated estriol: a prospective 2-year study.
    Phillips OP; Elias S; Shulman LP; Andersen RN; Morgan CD; Simpson JL
    Obstet Gynecol; 1992 Sep; 80(3 Pt 1):353-8. PubMed ID: 1379701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitivity and specificity of screening for Down syndrome with alpha-fetoprotein, hCG, unconjugated estriol, and maternal age.
    Macri JN; Kasturi RV; Krantz DA; Cook EJ
    Obstet Gynecol; 1991 Jun; 77(6):963-5. PubMed ID: 1709482
    [No Abstract]   [Full Text] [Related]  

  • 13. Correlation of ultrasound findings and biochemical markers in the second trimester of pregnancy in fetuses with trisomy 21.
    Souter VL; Nyberg DA; El-Bastawissi A; Zebelman A; Luthhardt F; Luthy DA
    Prenat Diagn; 2002 Mar; 22(3):175-82. PubMed ID: 11920888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maternal serum triple analyte screening and adverse pregnancy outcome.
    Milunsky A; Nebiolo L
    Fetal Diagn Ther; 1996; 11(4):249-53. PubMed ID: 8823604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-trimester maternal serum biochemical indicators in Down syndrome.
    Brock DJ; Barron L; Holloway S; Liston WA; Hillier SG; Seppala M
    Prenat Diagn; 1990 Apr; 10(4):245-51. PubMed ID: 1694994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second-trimester maternal serum screening for Down syndrome in in vitro fertilization pregnancies.
    Rice JD; McIntosh SF; Halstead AC
    Prenat Diagn; 2005 Mar; 25(3):234-8. PubMed ID: 15791658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prenatal trisomy 21 screening program using alpha-fetoprotein, human chorionic gonadotropin, and free estriol assays on maternal dried blood.
    Verloes A; Schoos R; Herens C; Vintens A; Koulischer L
    Am J Obstet Gynecol; 1995 Jan; 172(1 Pt 1):167-74. PubMed ID: 7531397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the Abbott system in maternal serum screening for Down syndrome: the AxSym analyzer, AFP and hCG reagents and Maciel Prenatal Interpretive Software.
    Muller F; Ngo S; Aegerter P; Le Bourdellès S; Taguel V; Rebiffé M; Faïna S; Giraudet P
    Clin Chim Acta; 1998 Sep; 277(1):65-75. PubMed ID: 9776046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The detection of non-immune hydrops through second-trimester maternal serum screening.
    Saller DN; Canick JA; Oyer CE
    Prenat Diagn; 1996 May; 16(5):431-5. PubMed ID: 8844001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A retrospective evaluation of maternal serum screening for the detection of fetal aneuploidy.
    Suzumori K; Tanemura M; Murakami I; Okada S; Natori M; Tanaka M; Takagi T; Sato A
    Prenat Diagn; 1997 Sep; 17(9):861-6. PubMed ID: 9316131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.